NCT07207148 - People With Multiple Sclerosis Treated With Ocrelizumab and GLP-1 Agonists | Biotech Hunter

Enrollment

100

Participants

Timeline

Start Date

October 15, 2025

Primary Completion Date

April 1, 2028

Study Completion Date

August 31, 2028

Conditions

Multiple Sclerosis

Interventions

DRUG

GLP-1

Glucagon-like peptide-1 agonist agent is the study agent of interest. This study will not supply the GLP-1 drug but depends on the patient's clinical prescription of this drug.

DRUG

Ocrelizumab (US)

All participants will be treated with Ocrelizumab for the indication of MS; however, the study will not provide Ocrelizumab as it will be part of the participant's routine clinical care.

Trial Locations (1)

02134

Northwestern Memorial Hospital, Boston